Biofrontera AG

Ludwig Lutter appointed new Chief Financial Officer effective March 1, 2021 - Seite 2

Ludwig Lutter has over 20 years of experience as CFO in numerous technology companies. Before joining Biofrontera, he served as CFO for brillen.de, Hotel Reservation Service, Intershop Communications AG, SOPHOS und Poet Holdings, Inc., which under his responsibility was brought public on both Nasdaq and the Frankfurt Stock Market, among other start-ups and IT-companies. Prior to that, he served in public accounting and tax consulting for KPMG and other public accounting firms. Ludwig holds a degree in business administration from the University of Texas, USA, and is qualified as a certified tax advisor in Germany.

"Biofrontera operates in a highly exciting market environment - the biotech market in the USA in particular holds enormous potential. My clear goal is to position the Company more firmly in the US market and to make a sustainable contribution to increasing the value of the Company. I am very much looking forward to a rewarding and successful collaboration with the team at Biofrontera," commented Ludwig Lutter.

-End-

For enquiries, please contact: Biofrontera AG Thomas Schaffer, Chief Financial Officer	[phone] [e-mail]
IR UK: Seton Services Toni Vallen	[phone]

About Biofrontera:

Biofrontera AG is a biopharmaceutical company specializing in the development and sale of dermatological drugs and medical cosmetics.

The Germany-based company, with over 150 employees worldwide, develops and markets innovative products for the care, protection and treatment of the skin. The company’s lead product is the combination of Ameluz, a topical prescription drug, and medical device BF-RhodoLED for the photodynamic therapy of certain superficial skin cancers and their precursors. Ameluz has been marketed in the EU since 2012 and in the United States since May 2016. In addition, the company markets the prescription medication Xepi for the treatment of impetigo in the United States. In the EU, the company also sells the dermocosmetics series Belixos, which offers specialized care for damaged or diseased skin.